CBS-3408
CBS-3408 is an orally active p38α MAPK inhibitor. CBS-3408 inhibits the release of TNFα and IL-1β. CBS-3408 reduces the disease severity of arthritis in mice. CBS-3408 inhibits TNFα release in a rat endotoxemia model. CBS-3408 can be used in studies related to endotoxemia and arthritis.
For research use only. We do not sell to patients.
- CAS No.: 452056-93-8
- Formula: C18H17FN4OS
- Molecular Weight:356.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
28.6 μM
Compound: 3; CBS-3408
|
Inhibition of human ERG expressed in HEK293 cells by patch clamp method
Inhibition of human ERG expressed in HEK293 cells by patch clamp method
|
[PMID: 28613871] |
In Vitro
CBS-3408 (Compound 3) inhibits LPS (HY-D1056)-induced IL-1β and TNFα release in human whole blood[1].
CBS-3408 (10 μM) inhibits JNK3 and p38β kinases by over 70%[1].
CBS-3408 (10 μM) inhibits CYP2C9 (46%) and CYP2D6 (45%), shows weak inhibitory activity against CYP1A2 (18%), and exhibits no relevant activity against CYP2C19 or CYP3A4[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | AUC0-t | T1/2 |
|---|---|---|---|---|---|---|
| Rat[1] | 30 mg/kg | p.o. | 1.0 h | 738 ng/mL | 4928 ng·h/mL | 3.0 h |
In Vivo
CBS-3408 (50 mg/kg; p.o.; twice daily) significantly reduces the disease severity of collagen (HY-NP003)-induced arthritis in male DBA/1 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Achieved 97% inhibition of plasma TNFα concentrations compared to control animals.
-
Animal Model:DBA/1 (male)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; twice daily
-
Result:Substantially reduced arthritic disease severity, with a notably lower arthritic score compared to vehicle control animals over the course of the study.
Showed no treatment-related toxicity aside from body weight loss identical to controls.
Chemical Information
-
CAS No. 452056-93-8
-
Molecular Weight 356.42
-
Formula C18H17FN4OS
-
SMILES
O=C(C)NC1=NC=CC(C2=C(C3=CC=C(C=C3)F)N=C(N2C)SC)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)